Loss of mitochondrial NAD+ as a unifying cause of heart failure
线粒体 NAD 丢失是心力衰竭的统一原因
基本信息
- 批准号:10708778
- 负责人:
- 金额:$ 3.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAtaxiaCardiacCardiac MyocytesCardiac OutputCardiovascular DiseasesCause of DeathCell LineCellsCessation of lifeCharacteristicsCitric Acid CycleComplexDataDepressed moodDevelopmentDiseaseEFRACEchocardiographyElectron TransportElectronsEnzymesEtiologyFibroblastsFriedreich AtaxiaFunctional disorderFutureGenerationsGlycolysis PathwayHeartHeart DiseasesHeart HypertrophyHeart MitochondriaHeart TransplantationHeart failureHumanHypertrophic CardiomyopathyIronLeft Ventricular RemodelingLeft ventricular structureLiteratureMaintenanceMediatingMediatorMetabolicMetabolismMitochondriaMitochondrial DiseasesMitochondrial MyopathiesMitochondrial ProteinsModelingMusMyocardial dysfunctionNADHNicotinamide adenine dinucleotideOrganellesOxygenPathogenesisPatientsPhasePlayPre-Clinical ModelProtocols documentationReportingResearchRespirationRoleStressSulfurSupplementationTestingTherapeuticTherapeutic EffectTherapeutic InterventionThickTissuesUnited Statesassociated symptomcell typecurative treatmentsexperienceexperimental studyfatty acid oxidationfrataxinheart functionimprovedin vivoischemic injuryknock-downloss of function mutationmetabolomicsmitochondrial dysfunctionmitochondrial metabolismmouse modelnicotinamide riboside supplementationnicotinamide-beta-ribosidepre-clinicalpreferenceprematurepreventreduce symptomsrespiratory
项目摘要
Project Summary
Heart disease results in over 650,000 deaths per year in the United States, and nearly half of all adults
are currently living with some form of cardiovascular disease. Currently there is no curative treatment
option except for a heart transplant. Thus, there is significant need for better therapeutic interventions.
Heart failure can take years to develop, but is ultimately characterized by a reduction in cardiac output.
There is a considerable body of research demonstrating maladaptive metabolic reprogramming of
cardiomyocytes at this stage, which contributes to heart dysfunction and adverse remodeling of the left
ventricle. The hypothesis detailed in this application proposes that nicotinamide adenine
dinucleotide (NAD+) deficiency in the mitochondria is sufficient to cause heart failure. Recent
literature demonstrates tissue-level NAD+ decline during ischemic injury. NAD+ precursors have been
found to be therapeutic for heart failure in multiple pre-clinical models. Preliminary data generated in
our lab suggests that the NAD+ precursor nicotinamide riboside (NR) prevented heart dysfunction,
protected mitochondrial function, and improved survival in a model of Friedreich’s Ataxia (FA), in which
mice typically develop progressive hypertrophic cardiomyopathy. This result suggests that NAD+
deficiency may be involved in the pathogenesis of heart failure in FA. Alternatively, it provides preclinical
evidence that NR is therapeutic in FA even without NAD+ deficiency, suggesting that boosting NAD+
levels in the heart tissue can be protective of heart function under mitochondrial stress. To address
these points, this proposal first aims to determine whether low mitochondrial NAD+ levels are observed
with loss of frataxin, and whether increasing mitochondrial NAD+ synthesis with NR ex vivo can directly
support mitochondrial respiration (Aim 1). This proposal also aims to define the metabolic
consequences of mitochondrial NAD+ deficiency in cardiomyocytes, to determine whether
mitochondrial NAD+ loss demonstrates characteristic metabolism of the hypertrophic heart in vivo (Aim
2). Together, this set of experiments will demonstrate whether NAD+ decline is a metabolic
consequence of frataxin loss and mitochondrial damage, and define the importance of mitochondrial
NAD+ maintenance in supporting the normal metabolism of cardiomyocytes. Further, it will provide
mechanistic understanding of the specific action of NAD+ precursors to protect against mitochondrial-
dysfunction mediated heart failure, which will inform future therapeutic interventions in progressive
heart disease.
项目摘要
在美国,心脏病每年导致超过65万人死亡,近一半的成年人死于心脏病。
目前患有某种形式的心血管疾病。目前还没有治愈性的治疗方法
除了心脏移植因此,非常需要更好的治疗干预。
心力衰竭可能需要数年时间才能发展,但最终的特征是心输出量减少。
有相当多的研究表明,
心肌细胞在这个阶段,这有助于心脏功能障碍和左心室的不良重塑
脑室本申请中详述的假设提出烟酰胺腺嘌呤
线粒体中的二核苷酸(NAD+)缺乏足以引起心力衰竭。最近
文献表明缺血性损伤期间组织水平的NAD+下降。NAD+前体已经被
在多个临床前模型中发现对心力衰竭有治疗作用。生成的初步数据
我们的实验室表明NAD+前体烟酰胺核苷(NR)预防心脏功能障碍,
保护线粒体功能,并改善弗里德赖希共济失调(FA)模型的存活率,其中
小鼠通常发展为进行性肥厚型心肌病。这一结果表明,NAD+
虚损可能参与了FA心力衰竭的发病机制。或者,它提供了临床前
有证据表明,即使没有NAD+缺乏,NR也能治疗FA,这表明增加NAD+
在线粒体应激下,心脏组织中的水平可以保护心脏功能。解决
鉴于以上几点,本提案首先旨在确定是否观察到低线粒体NAD+水平
以及用NR离体增加线粒体NAD+合成是否可以直接
支持线粒体呼吸(目的1)。该提案还旨在定义代谢
心肌细胞线粒体NAD+缺乏的后果,以确定是否
线粒体NAD+丢失显示了体内肥大心脏的特征性代谢(目的
2)。总之,这组实验将证明NAD+下降是否是代谢性的。
结果共济失调蛋白损失和线粒体损伤,并确定线粒体的重要性,
NAD+维持在支持心肌细胞的正常代谢中。此外,它将提供
对NAD+前体保护线粒体-
功能障碍介导的心力衰竭,这将为未来进行性心力衰竭的治疗干预提供信息。
心脏病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Caroline Perry其他文献
Caroline Perry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Caroline Perry', 18)}}的其他基金
Loss of mitochondrial NAD+ as a unifying cause of heart failure
线粒体 NAD 丢失是心力衰竭的统一原因
- 批准号:
10464920 - 财政年份:2022
- 资助金额:
$ 3.52万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 3.52万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 3.52万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 3.52万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 3.52万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 3.52万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 3.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)